Cover Image
Market Research Report

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 358349
Published Content info 46 Pages
Delivery time: 1-2 business days
Price
Back to Top
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2018
Published: September 11, 2018 Content info: 46 Pages
Description

Summary:

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Infectious Disease which include indications Type 2 Diabetes, Diabetes and Hepatitis B.

The latest report Free Fatty Acid Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1653TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
    • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Cadila Healthcare Ltd
    • Daiichi Sankyo Co Ltd
    • Hyundai Pharmaceutical Co Ltd
    • Johnson & Johnson
    • Merck & Co Inc
    • Takeda Pharmaceutical Co Ltd
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
    • AM-1638 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1558 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fasiglifam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TUG-770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYDG-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development
      • Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes
      • May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society
      • Aug 22, 2012: Takeda Launches Phase III Clinical Trial In Asia For TAK-875 To Treat Diabetes
      • Feb 27, 2012: Takeda Announces Publication Of Phase II Data Of TAK-875 In The Lancet, Demonstrates Improved Glycemic Control In Patients With Type 2 Diabetes
      • Oct 18, 2011: Takeda Initiates Phase III Clinical Trial Program In US, Latin America, And Europe For Investigational Type 2 Diabetes Therapy TAK-875
      • Sep 12, 2011: Takeda's TAK-875 Enters Into Phase III Clinical Trials For Treatment Of Type 2 Diabetes In Japan
      • Jun 28, 2011: Takeda Presents Late Breaking Data Of TAK-875 At American Diabetes Association 71st Annual Scientific Sessions
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Amgen Inc, H2 2018
  • Pipeline by Cadila Healthcare Ltd, H2 2018
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018
  • Pipeline by Johnson & Johnson, H2 2018
  • Pipeline by Merck & Co Inc, H2 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
Back to Top